Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) FCF Margin (2016 - 2025)

Iradimed (IRMD) has disclosed FCF Margin for 13 consecutive years, with 60.3% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 3714.0% to 60.3% in Q3 2025 year-over-year; TTM through Sep 2025 was 35.87%, a 126.0% increase, with the full-year FY2024 number at 33.88%, up 1420.0% from a year prior.
  • FCF Margin was 60.3% for Q3 2025 at Iradimed, up from 25.04% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 60.3% in Q3 2025 to a low of 18.14% in Q2 2023.
  • A 5-year average of 24.63% and a median of 25.04% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -2918bps in 2023, then soared 5441bps in 2024.
  • Iradimed's FCF Margin stood at 25.72% in 2021, then dropped by -20bps to 20.55% in 2022, then surged by 186bps to 58.76% in 2023, then dropped by -9bps to 53.59% in 2024, then increased by 13bps to 60.3% in 2025.
  • Per Business Quant, the three most recent readings for IRMD's FCF Margin are 60.3% (Q3 2025), 25.04% (Q2 2025), and 3.05% (Q1 2025).